Opendata, web and dolomites

GLIOMARK SIGNED

Validation of blood-brain-barrier permeability as a glioma biomarker by means of the radiotracer 99mTc-tetrofosmin and single-photon emission computer tomography

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GLIOMARK project word cloud

Explore the words cloud of the GLIOMARK project. It provides you a very rough idea of what is the project "GLIOMARK" about.

first    single    sensitivity    invasive    poor    glioma    outcome    guarantee    niche    hence    diagnose    tlr    blood    aggressiveness    imaging    subsequent    market    disease    selling    computer    confirmation    containing    point    expensive    gliomas    prognosis    resonance    innovative    99mtc    approval    replace    permeability    leader    biomarker    latter    reconstituted    radiotracer    sale    designation    therapies    opportunity    orphan    validate    combination    global    diseases    assesses    hospitals    detect    magnetic    tolerated    reproducibility    diagnosis    specificity    sme    gliotect    exclusivity    accomplished    mography    bbb    vivo    fast    diagnostic    barrier    rare    chemical    gliomark    preparation    pertechnetate    exclude    greek    tetrofosmin    unable    reliability    tomography    handling    objective    yield    photon    emission    clinically    grade    diagnostics    proactina    reliably    kit    aggregated    grading    lifted    safe    differential    tumor    technique    biopsies    spect    affordable    distinguish    speciality    ttf    brain    instructions    validated   

Project "GLIOMARK" data sheet

The following table provides information about the project.

Coordinator
CONSULTECH TECHNOLOGIEBERATUNG GMBH 

Organization address
address: MORGENSTERNSTRASSE 24
city: BERLIN
postcode: 12207
website: www.consultech.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.gliomark.eu
 Total cost 4˙705˙344 €
 EC max contribution 4˙705˙344 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CONSULTECH TECHNOLOGIEBERATUNG GMBH DE (BERLIN) coordinator 3˙167˙094.00
2    PRO-ACTINA CHIMIKI TECHNOLOGIA ANONIMI ETAIRIA EL (MAROUSI ATHENS) participant 1˙538˙250.00

Map

 Project objective

Objective of GLIOMARK is to clinically validate the permeability of the blood brain barrier (BBB) as an in vivo biomarker for the diagnosis and grading of gliomas. This will be accomplished by means of the radiotracer 99mTc-tetrofosmin (TTF) and the imaging technique Single-Photon Emission Computer To-mography (SPECT). The outcome of GLIOMARK is GlioTect, a diagnostic kit containing handling/diagnostic instructions and tetrofosmin. The latter has to be reconstituted with 99mTc pertechnetate to yield TTF, which will be used in combination with SPECT. Often computer tomography or magnetic resonance imaging are unable to detect low-grade gliomas or distinguish glioma from other diseases. Hence, brain biopsies are necessary for confirmation of diagnosis and grading of gliomas. GlioTect with TTF/SPECT enables reliable, fast differential diagnosis and grading of gliomas as non-invasive method. This has an immediate impact on the type and aggressiveness of subsequent therapies. Gliomas are recognized as a rare tumor disease with poor prognosis and orphan diagnostic designation for GlioTect will guarantee 10 years of market exclusivity upon approval. ProActina, a Greek chemical-speciality SME having identified this innovative niche market opportunity could become global market leader in glioma diagnostics. Development is at TLR level 6-7 and will be lifted to 9. Expected market application is the sale of GlioTect for preparation of TTF for use with SPECT. End users are hospitals that use the kit to reliably diagnose or exclude gliomas without the need for expensive equipment. Taken together, the aggregated unique selling point of SPECT in combination with TTF (generated by means of GlioTect) is the first ever and only glioma diagnostic, which assesses a clinically validated glioma biomarker, has high reliability, reproducibility, sensitivity, as well as specificity, which is used to replace an invasive method, is safe, well tolerated, widely available and more affordable

 Deliverables

List of deliverables.
Set up project homepage Websites, patent fillings, videos etc. 2019-07-25 13:49:19

Take a look to the deliverables list in detail:  detailed list of GLIOMARK deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLIOMARK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLIOMARK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More